Loading…
Silexion Therapeutics Corp is projected to rise to $0.4369 by 2027, a +5% move from its current price of $0.4163. SLXN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.3753 | $0.4158 | $0.4605 | -0.13% |
| May 30 | $0.3593 | $0.4152 | $0.4799 | -0.26% |
| May 31 | $0.3473 | $0.4147 | $0.4951 | -0.39% |
| Jun 1 | $0.3375 | $0.4141 | $0.5082 | -0.53% |
| Jun 2 | $0.329 | $0.4136 | $0.5199 | -0.66% |
| Jun 3 | $0.3215 | $0.413 | $0.5307 | -0.79% |
| Jun 4 | $0.3147 | $0.4125 | $0.5407 | -0.92% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3147 | $0.4125 | $0.5407 | -0.92% |
| Week 2 | $0.2787 | $0.4087 | $0.5993 | -1.83% |
| Week 3 | $0.2534 | $0.4049 | $0.6472 | -2.73% |
| Week 4 | $0.2335 | $0.4012 | $0.6895 | -3.62% |
| Week 5 | $0.217 | $0.3976 | $0.7283 | -4.50% |
| Week 6 | $0.203 | $0.3939 | $0.7645 | -5.38% |
| Week 7 | $0.1907 | $0.3903 | $0.7988 | -6.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Silexion Therapeutics Corp is a biopharmaceutical company focused on discovering and developing RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. Its work centers on using its proprietary LODER delivery platform to target solid tumors. Its products include SiG12D-LODER, which has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER, which is in pre-clinical studies to target Glioblastoma Multiform.
Silexion Therapeutics Corp has a collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN operates in the healthcare sector with a current price of $0.4163 and a market capitalization of $1.74M. Its market rank is 5422. The 30-day forecast shows a path that begins at a current level and evolves over time, with 2026 averaging around $0.4163 and longer-term estimates rising toward the mid-to-upper range of the forecast.
Notably, the 2040 and 2050 forecasts place average levels at $0.8852 and $1.28 respectively, signaling an elevated longer-term outlook.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 35.4% below — buyers have tended to step in here.
The nearest ceiling, 159.4% above — a clean break opens room to run.
A major ceiling 445.3% above — clearing it would confirm fresh momentum.
Key SLXN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLXN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4693 | Sell | $0.4352 | Sell |
| MA 10 | $0.4228 | Sell | $0.4518 | Sell |
| MA 20 | $0.5003 | Sell | $0.5378 | Sell |
| MA 50 | $0.8796 | Sell | $0.8614 | Sell |
| MA 100 | $1.36 | Sell | $1.56 | Sell |
| MA 200 | $2.67 | Sell | $5.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.96 | Neutral |
| Stoch RSI (14) | 79.09 | Neutral |
| CCI (20) | -68.33 | Neutral |
| Williams %R (14) | -53.65 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -21.39 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 46.35 | Neutral |
| TRIX (15) | -2.93 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 52.60 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.49 | Sell |
| ADX (14) | 40.25 | Sell |
| ATR (14) | 0.06 | Info |
The near-term technical picture is NEUTRAL, with RSI at 40. The 50-day simple moving average stands at $0.8796 and the 200-day simple moving average at $2.67. The stock’s nearest support is indicated at $0.269 and resistance at $1.08. The 30-day price range spans from $0.2121 to $0.8172. Annualized volatility is reported at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.269 | $0.4163 | $0.5934 | 0% | Neutral | |
| $0.3144 | $0.4369 | $0.657 | +5% | Neutral | |
| $0.3694 | $0.5448 | $0.8708 | +31% | Bullish | |
| $0.394 | $0.6115 | $1.02 | +47% | Bullish | |
| $0.3209 | $0.5219 | $0.9099 | +25% | Bullish | |
| $0.3026 | $0.5143 | $0.9276 | +24% | Bullish | |
| $0.2668 | $0.4728 | $0.8789 | +14% | Neutral | |
| $0.2596 | $0.479 | $0.9148 | +15% | Neutral | |
| $0.3764 | $0.7225 | $1.41 | +74% | Bullish | |
| $0.3823 | $0.7627 | $1.53 | +83% | Bullish | |
| $0.3984 | $0.8852 | $1.95 | +113% | Bullish | |
| $0.5763 | $1.28 | $2.95 | +208% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.269 | $0.4163 | $0.4955 | +0.00% |
| June 2026 | $0.3295 | $0.3952 | $0.4911 | -5.07% |
| July 2026 | $0.3027 | $0.3692 | $0.4706 | -6.57% |
| August 2026 | $0.3166 | $0.3913 | $0.5084 | +5.97% |
| September 2026 | $0.3217 | $0.4021 | $0.5306 | +2.77% |
| October 2026 | $0.3007 | $0.3797 | $0.5081 | -5.57% |
| November 2026 | $0.3074 | $0.3917 | $0.5305 | +3.15% |
| December 2026 | $0.337 | $0.4331 | $0.5934 | +10.58% |
Click any year to see its month-by-month SLXN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SLXN is projected to trade between $0.269 and $0.5934, averaging $0.4163 — a potential gain of 0% from today's $0.4163. Price action looks broadly range-bound.
Silexion Therapeutics Corp's 2027 outlook centres on $0.4369, within a $0.3144 to $0.657 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, SLXN could reach as high as $0.8708, with a base case around $0.5448 and support toward $0.3694 — roughly +31% from $0.4163. Momentum favours further upside here.
Expect SLXN to range from $0.394 to $1.02 through 2029. The $0.6115 average target implies a +47% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The SLXN price prediction for 2030 points to an average of $0.5219 (low $0.3209, high $0.9099) — a potential gain of +25% on today's $0.4163. Momentum favours further upside here.
In 2031, SLXN is projected to trade between $0.3026 and $0.9276, averaging $0.5143 — a potential gain of +24% from today's $0.4163. That is -1% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Silexion Therapeutics Corp's 2032 outlook centres on $0.4728, within a $0.2668 to $0.8789 range. That is -8% versus the projected 2031 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2033, SLXN could reach as high as $0.9148, with a base case around $0.479 and support toward $0.2596 — roughly +15% from $0.4163. A consolidation phase looks the most probable path here.
Expect SLXN to range from $0.3764 to $1.41 through 2034. The $0.7225 average target implies a +74% move from current prices. That is up +51% on the projected 2033 average. Momentum favours further upside here.
The SLXN price prediction for 2035 points to an average of $0.7627 (low $0.3823, high $1.53) — a potential gain of +83% on today's $0.4163. Buyers look set to stay in control over this stretch.
In 2040, SLXN is projected to trade between $0.3984 and $1.95, averaging $0.8852 — a potential gain of +113% from today's $0.4163. That is up +16% on the projected 2035 average. Momentum favours further upside here.
Silexion Therapeutics Corp's 2050 outlook centres on $1.28, within a $0.5763 to $2.95 range. That is up +45% on the projected 2040 average. That marks a +208% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLXN today (≈ 2,402.11386 SLXN) could be worth
$3,076.23
+$2,076.23 (+208%) by 2050 · US Dollar
Based on the average projected SLXN price of $1.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLXNwould be worth at today's price.
$1,000 invested in SLXN on May 27, 2025 (≈ 66.006602 SLXN) would be worth
$27.48
-$972.52 (-97.3%) today · 0.03× · US Dollar
Based on a SLXN entry price of $15.15 vs. today's $0.4163.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.53 | $785.47 | -21.5% |
| 1 month ago | $0.73 | $570.27 | -43.0% |
| 3 months ago | $1.74 | $239.25 | -76.1% |
| 6 months ago | $2.83 | $147.1 | -85.3% |
| 1 year ago | $15.15 | $27.48 | -97.3% |
| All time (5.0y) ago | $144.15 | $2.89 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLXN forecast.
Our base-case forecast reaches $0.83 around 2040.
Implied market cap at $0.83: $3.48M
The multi-year forecast shows a variable path with gradual progression and notable upward potential in later years. For 2028 the average price is $0.5448 with a bullish sentiment and a 30.9% projected ROI. In 2029 the average is $0.6115 with a 46.9% ROI and bullish sentiment, followed by 2030 at $0.5219 (25.4% ROI, bullish).
2031 is $0.5143 (23.5% ROI, bullish) and 2032 is $0.4728 (13.6% ROI, neutral), then 2033 at $0.479 (15.1% ROI, neutral). The forecast sees a stronger ascent in 2034 with $0.7225 (73.6% ROI, bullish) and 2035 at $0.7627 (83.2% ROI, bullish). By 2040 the average increases to $0.8852 with a 112.7% ROI and bullish sentiment, and by 2050 the average is $1.28 with a 207.6% ROI and bullish sentiment, while the min/max for 2050 are $0.5763 and $2.95 respectively.
Overall, the longer-horizon figures imply upside potential with max forecasts reaching $2.95 and a min near $0.5763, though these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $0.5219; Min $0.3209; Max $0.9099; ROI 25.4%; sentiment BULLISH.
2029 max $1.02; Min $0.394; Avg $0.6115; ROI 46.9%; sentiment BULLISH.
Avg $0.8852; Min $0.3984; Max $1.95; ROI 112.7%; sentiment BULLISH.
Avg $1.28; Min $0.5763; Max $2.95; ROI 207.6%; sentiment BULLISH.
RSI14 40; SMA50 $0.8796; SMA200 $2.67; Support $0.269; Resistance $1.08; 30-day range $0.2121-$0.8172.
Silexion Therapeutics Corp Community Discussion
0Share your Silexion Therapeutics Corp price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.